MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF), a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection, is moving toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America's mining sector.
The company recently appointed Chilean drug policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio's transition from development to market entry. Leyton's expertise in Chilean regulatory and industrial landscapes is expected to facilitate adoption in the mining sector, which employs more than 200,000 workers and presents a high-risk environment where impairment detection can significantly enhance safety.
MindBio's technology analyzes voice patterns to detect intoxication or impairment without biological testing, positioning the platform as a scalable tool for workplace safety in mining and other high-risk industries. Management believes the non-invasive nature of voice analysis offers advantages over traditional methods, such as breathalyzers or saliva tests, by enabling frequent, unobtrusive screening that can be integrated into daily operations.
The company is preparing to deploy its platform in industrial environments beginning in 2026, with Chile's mining sector representing an early target market. The mining industry in South America, particularly in Chile, faces stringent safety regulations and high costs associated with accidents, creating a strong demand for innovative safety technologies.
To support commercialization activities, MindBio recently closed an upsized non-brokered private placement of up to $1.5 million. This capital is expected to fund further development, regulatory approvals, and initial marketing efforts in the region.
The appointment of Felipe Leyton underscores MindBio's strategic focus on the South American market. Leyton's background in drug policy and his connections within Chilean industry are anticipated to accelerate partnerships and pilot programs with mining companies.
As MindBio progresses toward commercial deployment, the success of its platform in the mining sector could pave the way for broader applications in other industries such as transportation, construction, and manufacturing, where impairment detection is critical for safety.
For the latest news and updates relating to MBQIF, visit the company's newsroom at https://ibn.fm/MBQIF.
BioMedWire (BMW) is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.
